此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation

2026年9月2日 更新者:Servier

A Phase 1/2, Dose Optimization and Dose Expansion, Multicenter, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Menin Inhibitor S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Patients With Relapsed or Refractory Acute Myeloid Leukemia With NPM1c Mutation

The objective of this study is to establish the efficacy, safety, and tolerability of S243249 and to establish the recommended phase 2 dose (RP2D) of S243249 monotherapy in participants with relapsed/refractory (R/R) acute leukemia with select mutations. Phase 1 dose optimization will determine the RP2D to be used in Phase 2 dose expansion. The study will include a screening period, a treatment period consisting of continuous 28-day cycles of treatment, a safety follow-up period and a long-term follow-up period. Participants may undergo blood tests, electrocardiogram (ECG), bone marrow aspirations, vital sign checks, questionnaires, and physical exams.

研究概览

研究类型

介入性

注册 (估计的)

80

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Aged ≥ 18 years old.
  • Negative serum pregnancy (β-hCG) test in women of childbearing potential at screening
  • Cytomorphology-confirmed diagnosis of R/R acute leukemia (including AML, ALL, and mixed lineage leukemia) according to the WHO criteria in 2022. R/R acute leukemia must meet at least one of the following conditions:
  • Primary refractory disease, defined as non-response to 2 courses of standard induction therapy.
  • R/R disease, defined as > 5% blasts on bone marrow aspirate (BMA) / bone marrow biopsy (BMB) after completing prior therapy.
  • Relapse after allogeneic hematopoietic stem cell transplantation (HSCT), autologous HSCT, or immunotherapy such as chimeric antigen receptor T cell therapy (CAR-T) and T cell engager (TCE).
  • Participants with secondary AML or AML transformed from myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), etc., can be included in the study, if they meet the above criteria after the disease has transformed into AML.
  • Confirmation of KMT2At, NUP98t, or NPM1c mutation using next generation sequencing (NGS), fluorescence in situ hybridization (FISH), or polymerase chain reaction (PCR) based test in an accredited local or central lab within 28 days before start of treatment.
  • Peripheral blood white blood cell (WBC) count ≤ 25 mm3 (hydroxyurea, steroids, or vincristine to reduce peripheral WBC count is permitted).
  • Participants will be at least 2 weeks from prior therapy (except hydroxyurea, vincristine, or steroids and prespecified prephase therapy) and recovered from nadir to no worse than Grade 1 nonhematological toxicity from the prior treatment.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
  • Adequate electrolytes, liver, kidney, and cardiac function
  • Sexually active male or female participants of childbearing potential must agree to use 2 medically accepted forms of effective contraception, e.g., oral, parenteral, or implanted contraceptives; intrauterine devices; and barrier methods with spermicides, during the study and for 3 or 6 months after the final administration of investigational medicinal product (IMP), in males and females respectively. Egg donation is not allowed during the study or within 6 months of the last dose of S243249.
  • Male participants with women of childbearing potential (WOCBP) partners must use a condom during the study and for at least 3 months after the final administration of IMP.

Exclusion Criteria:

  • Active central nervous system (CNS) leukemia (including imaging abnormalities and cerebrospinal fluid (CSF) smear or flow cytometry indicating leukemia cells)).
  • Active disseminated intravascular coagulation (DIC).
  • Active uncontrolled infection (prophylaxis because of absolute neutrophil count [ANC] is excepted).
  • Diagnosis of acute promyelocytic leukemia (APL, M3).
  • Corrected QT interval calculated by Fridericia (QTcF) > 450 msec on screening ECG.
  • Participants with an increased pro-arrhythmic risk such as those with congenital long QT syndrome.
  • Uncontrolled or severe cardiovascular disease, , within 12 months.
  • Uncontrolled serious arrhythmias.
  • Clinically significant pericardial disease.
  • History of other malignancy within the past 5 years.
  • Participants who receive autologous hematopoietic stem cell transplantation (ASCT) or CAR-T therapy within 60 days of the first dose of S243249 or have not yet recovered from toxicity related to ASCT or CAR-T therapy.
  • Participants who receive allogeneic HSCT within 100 days of the first dose of S243249, still have active acute or chronic graft versus host disease (GVHD), or still require immune-modulating therapy.
  • Have an active infection of hepatitis B or hepatitis C.
  • Have advanced liver disease or cirrhosis.
  • Uncontrolled human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome related illness.
  • Pregnant and/or breast-feeding (lactating) women.
  • Participant has received anti-leukemia treatment, including chemotherapy, radiation therapy, targeted small molecule agents, biologic agents, immunotherapy, or any other investigational therapy (excluding hydroxyurea, or vincristine for cytoreduction) within 2 weeks prior to the first dose of S243249.
  • Previous treatment targeting menin, dose optimization phase only.
  • Any concomitant participation in another therapeutic clinical trial is prohibited. Any participation in another nontherapeutic clinical trial could be approved by the medical monitor.
  • Participants taking medications known to prolong the QT/QTc interval (with the exception of necessary azole antifungals).
  • Ongoing toxicity from prior anti-leukemia therapy that has not resolved to Grade 1 7 days prior to the first dose of S243249 has to be approved by the medical monitor.
  • Uncontrolled active infection
  • Known allergy or hypersensitivity to menin inhibitors or any component of S243249.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Phase 1 Dose Optimization: Cohort 1
For participants without strong CYP3A4 inhibitors
Taken twice daily by mouth
实验性的:Phase 1 Dose Optimization: Cohort 2
For participants without strong CYP3A4 inhibitors
Taken twice daily by mouth
实验性的:Phase 1 Dose Optimization: Cohort 3
For participants with strong CYP3A4 inhibitors
Taken twice daily by mouth
实验性的:Phase 1 Dose Optimization: Cohort 4
For participants with strong CYP3A4 inhibitors
Taken twice daily by mouth

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Incidence of Adverse Events (AEs)
大体时间:Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Severity of AEs
大体时间:Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Number of changes in laboratory values
大体时间:Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Number of changes in electrocardiogram (ECG)
大体时间:Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Number of changes in vital signs
大体时间:Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Number of AEs leading to dose interruption
大体时间:Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Number of AEs leading to dose modification
大体时间:Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Number of AEs leading to dose delays
大体时间:Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Number of AEs leading to permanent treatment discontinuation
大体时间:Through Safety Follow-up (Approximately 3 years)
Through Safety Follow-up (Approximately 3 years)
Complete remission (CR) + Complete remission with partial recovery of hematology (CRh) rate
大体时间:Through Long-term Follow-up (Approximately 5 years)
Through Long-term Follow-up (Approximately 5 years)

次要结果测量

结果测量
措施说明
大体时间
Overall response rate (ORR)
大体时间:Through Long-term Follow-up (Approximately 5 years)
CR + CRh + Complete remission with incomplete hematological recovery (CRi) + Morphologically leukemic state (MLFS) + Partial remission (PR)
Through Long-term Follow-up (Approximately 5 years)
Composite complete remission (CRc) rate
大体时间:Through Long-term Follow-up (Approximately 5 years)
CRc is CR + CRh + CRi
Through Long-term Follow-up (Approximately 5 years)
CR rate
大体时间:Through Long-term Follow-up (Approximately 5 years)
Through Long-term Follow-up (Approximately 5 years)
Rate of CR/CRh Minimal residual disease (MRD) negativity
大体时间:Through Long-term Follow-up (Approximately 5 years)
Through Long-term Follow-up (Approximately 5 years)
Duration of response (DOR)
大体时间:Through Long-term Follow-up (Approximately 5 years)
Measured from the date of first achievement of CR/CRh, CR, CR/CRh MRD negativity, CRc and ORR until hematologic relapse or death from any cause
Through Long-term Follow-up (Approximately 5 years)
Time to response (TTR)
大体时间:Through Long-term Follow-up (Approximately 5 years)
Measured from the date of first dose administration until the first achievement of CR/CRh, CR, CR/CRh MRD negativity, CRc and ORR
Through Long-term Follow-up (Approximately 5 years)
Transfusion independence 56 days (TI-56)
大体时间:Through Long-term Follow-up (Approximately 5 years)
The absence of red blood cells and platelet transfusions lasting for 56 consecutive days during which the patient is either on Investigational medicinal product (IMP) or following discontinuation from IMP but before the start of new therapy.
Through Long-term Follow-up (Approximately 5 years)
Transfusion independence 112 days (TI-112)
大体时间:Through Long-term Follow-up (Approximately 5 years)
The absence of red blood cells and platelet transfusions lasting for 112 consecutive days during which the patient is either on IMP or following discontinuation from IMP but before the start of new therapy.
Through Long-term Follow-up (Approximately 5 years)
Event free survival (EFS)
大体时间:Through Long-term Follow-up (Approximately 5 years)
Through Long-term Follow-up (Approximately 5 years)
Cumulative relapse rate (CIR)
大体时间:Through Long-term Follow-up (Approximately 5 years)
Through Long-term Follow-up (Approximately 5 years)
Cumulative mortality (CID)
大体时间:Through Long-term Follow-up (Approximately 5 years)
Through Long-term Follow-up (Approximately 5 years)
Overall survival (OS)
大体时间:Through Long-term Follow-up (Approximately 5 years)
Through Long-term Follow-up (Approximately 5 years)
Quality of Life (QoL) measured via EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L)
大体时间:Through Safety Follow-up (Approximately 3 years)
EQ-5D-5L scores range from 0-5 with 5 representing the best QoL.
Through Safety Follow-up (Approximately 3 years)
QoL measured via Hematological malignancy specific patient-reported outcome (HM-PRO)
大体时间:Through Safety Follow-up (Approximately 3 years)
HM-PRO Part A scores range from 0 to 48 and Part B scores from 0 to 36, with a higher score representing the largest impact on quality of life.
Through Safety Follow-up (Approximately 3 years)
Health economic outcomes measured via EQ-5D-5L
大体时间:Through Safety Follow-up (Approximately 3 years)
EQ-5D-5L scores range from 0-1 with 1 representing the best health economic outcomes.
Through Safety Follow-up (Approximately 3 years)
Health economic outcomes measured via HM-PRO
大体时间:Through Safety Follow-up (Approximately 3 years)
HM-PRO scores range from 0 to 48, with a higher score representing the largest impact on health economic outcomes.
Through Safety Follow-up (Approximately 3 years)
Ability to proceed to hematopoietic stem cell transplantation (HSCT) as assessed by the investigator
大体时间:Through Long-term Follow-up (Approximately 5 years)
Through Long-term Follow-up (Approximately 5 years)
Plasma concentration of S243249 and relevant metabolites
大体时间:Through Cycle 6 Day 1 (each cycle is 28 days)
Plasma samples will be analyzed to determine concentrations of S243249 and relevant metabolites
Through Cycle 6 Day 1 (each cycle is 28 days)
Tmax
大体时间:Through Cycle 6 Day 1 (each cycle is 28 days)
Time to observed maximum plasma concentration of S243249 and relevant metabolites
Through Cycle 6 Day 1 (each cycle is 28 days)
Cmax
大体时间:Through Cycle 6 Day 1 (each cycle is 28 days)
Maximum plasma concentration of S243249 and relevant metabolites
Through Cycle 6 Day 1 (each cycle is 28 days)
AUC0-t
大体时间:Through Cycle 6 Day 1 (each cycle is 28 days)
Area under the plasma concentration-time curve from time 0 to time t of S243249 and relevant metabolites
Through Cycle 6 Day 1 (each cycle is 28 days)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月20日

初级完成 (估计的)

2029年8月11日

研究完成 (估计的)

2030年8月25日

研究注册日期

首次提交

2026年7月13日

首先提交符合 QC 标准的

2026年7月22日

首次发布 (实际的)

2026年7月23日

研究记录更新

最后更新发布 (实际的)

2026年9月3日

上次提交的符合 QC 标准的更新

2026年9月2日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • BN104-102
  • 2025 (美国 NIH 拨款/合同:Faculty of Social Sciences Scientific Grant at the University of Gdańsk)
  • 2025-524689-74-00 (克蒂斯)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.

Access can be requested for all interventional clinical studies:

  • used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
  • where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.

In addition, access can be requested for all interventional clinical studies in patients:

  • sponsored by Servier
  • with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

IPD 共享时间框架

After Marketing Authorization in EEA or US if the study is used for the approval.

IPD 共享访问标准

Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅